Lumida
/GOSS
⌘K
Gossamer Bio Inc

Gossamer Bio Inc

GOSS
$0.17USD-0.23%-0.00 today

MARKET CAP

83.2M

P/E (TTM)

FWD P/E

DAY RANGE

$0 – $0

52W RANGE

$0
$4

AI Summary

Stalk
Sell NowMedium

GOSS remains in a Stage 4 decline with both long- and short-term downtrends intact. Price continues to trade below the 9, 21, 50, and 200 EMAs, with repeated rejections at those levels. The active Post-Capitulation pattern shows forced selling has exhausted but no base has formed, reinforcing a bearish medium-term stance. Short-term momentum and EMA rejection favor immediate downside participation, warranting a sell-now posture despite oversold context.

  • Serolutinib improved six-minute walk distance by 28.2m vs. 13.5m placebo.
  • $99M cash runway supports operations into Q1 2027.
  • Earnings yield sits at -3.27, undermining return prospects.
Full analysis →
Insider Trades10 trades
DateSideTickerInsiderRoleSharesPriceMkt Cap52W High52W LowValue% ChgRuleAI View
Jun 24, 2024SellGOSSRichard ArandaChief Medical Officer1,908$0.66$83.2M-95.60%+49.47%$1.3K-0.96%Sell Now
Jun 21, 2024BuyGOSSFaheem HasnainPresident & CEO372,000$0.67$83.2M-95.60%+49.47%$250.3K+7.39%Sell Now
Jun 18, 2024BuyGOSSBryan GiraudoCOO/CFO100,000$0.59$83.2M-95.60%+49.47%$59.1K+26.32%Sell Now
Jun 17, 2024BuyGOSSRobert Paul Jr SmithChief Commercial Officer25,000$0.60$83.2M-95.60%+49.47%$15.1KSell Now
Mar 27, 2024SellGOSSWaage ChristianEVP, Tech Ops and Admin6,430$1.16$83.2M-95.60%+49.47%$7.4K-1.09%Sell Now
Mar 27, 2024SellGOSSBryan GiraudoCOO/CFO6,430$1.16$83.2M-95.60%+49.47%$7.4K-6.48%Sell Now
Mar 27, 2024SellGOSSFaheem HasnainPresident & CEO23,172$1.16$83.2M-95.60%+49.47%$26.8K-16.15%Sell Now
Mar 18, 2024SellGOSSRichard ArandaChief Medical Officer4,018$1.33$83.2M-95.60%+49.47%$5.3K-1.98%Sell Now
Mar 18, 2024SellGOSSCaryn PetersonEVP, Regulatory Affairs4,018$1.33$83.2M-95.60%+49.47%$5.3K-7.46%Sell Now
Nov 13, 2023BuyGOSSBryan GiraudoCOO/CFO200,000$0.56$83.2M-95.60%+49.47%$112.9K+111.10%Sell Now